ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
March 13, 2023 08:00 ET
|
ProPhase Labs, Inc.
Presentation to be given in Collaboration with the Mayo Clinic at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Company’s findings to be presented in a headline Poster...
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
November 08, 2022 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly...
ProPhase Labs Announces New $6 Million Stock Repurchase Plan
July 26, 2022 08:00 ET
|
ProPhase Labs, Inc.
Company also provides additional information on ProPhase BioPharma Garden City, NY, July 26, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a rapidly growing and...
ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology
June 28, 2022 08:30 ET
|
ProPhase Labs, Inc.
Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G Garden City, NY, June 28, 2022 (GLOBE...